Introduction
============

Dengue viral infection is one of the most challenging tropical diseases internationally.[@b1-rmhp-7-045] The infection may be complicated with hypotension[@b2-rmhp-7-045] and bleeding abnormality, leading to high mortality.[@b2-rmhp-7-045],[@b3-rmhp-7-045] The infection also has high economic impact due to high cost of care.[@b4-rmhp-7-045],[@b5-rmhp-7-045] Prognostication of disease severity may help clinicians decide which patients should be admitted to hospital, or which patients may safely be treated as outpatients.[@b6-rmhp-7-045]

A clinical decision rule is a clinical tool that quantifies the individual contributions that various components of the history, physical examination, and basic laboratory results make toward the diagnosis, prognosis, or likely response to treatment in a patient. Clinical decision rules attempt to formally test, simplify, and increase the accuracy of clinicians' diagnostic and prognostic assessments.[@b7-rmhp-7-045]

A prediction rule for severe dengue infection based on clinical signs and simple laboratory results was successful in predicting dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS).[@b8-rmhp-7-045] Decision tree algorithms,[@b9-rmhp-7-045]--[@b12-rmhp-7-045] diagnostic decision algorithms,[@b13-rmhp-7-045] the pediatric logistic organ dysfunction score,[@b14-rmhp-7-045]--[@b18-rmhp-7-045] and the disseminated intravascular coagulation scoring system[@b19-rmhp-7-045],[@b20-rmhp-7-045] were also developed. Other studies were also designed to differentiate dengue fever (DF),[@b9-rmhp-7-045],[@b10-rmhp-7-045] types of dengue infection (DF, DHF, or DSS),[@b10-rmhp-7-045],[@b12-rmhp-7-045],[@b13-rmhp-7-045] fatal conditions,[@b12-rmhp-7-045] development of DHF,[@b11-rmhp-7-045] multiple organ dysfunctions,[@b14-rmhp-7-045]--[@b16-rmhp-7-045] DSS mortality,[@b17-rmhp-7-045],[@b18-rmhp-7-045] and disseminated intravascular coagulation.[@b19-rmhp-7-045],[@b20-rmhp-7-045]

Earlier, we developed a scoring system to help screen patient severity[@b21-rmhp-7-045] based on clinical parameters and simple laboratory tests. The present study was conducted to externally validate this scoring system to patients in different settings.

Materials and methods
=====================

Patients
--------

Medical files of patients with dengue viral infection aged 1--15 years were retrieved from hospital database, all cases were included in the study. The following International Classification of Diseases (ICD)-10 codes were used: A-90 (DF), A-91 (DHF), and A-910 (DHF with shock).

Definition of dengue severity
-----------------------------

The severity of dengue infection was defined by the following criteria, as in the previous study[@b21-rmhp-7-045]

1.  Dengue infection -- acute or abrupt onset of fever, accompanied by a positive tourniquet test, and white blood count ≤5,000/μL[@b22-rmhp-7-045]

2.  DHF -- all items of the following:[@b23-rmhp-7-045]

    -   Acute or abrupt fever for 2--7 days

    -   At least one of the following bleeding episodes:

        1.  -- Positive tourniquet test

        2.  -- Petechiae, ecchymoses, or purpura

        3.  -- Bleeding from mucosa, gastrointestinal tract, injection sites, or other location

        4.  -- Hematemesis or melena

    -   Platelets ≤100,000/μL

    -   At least one of the following plasma leakage evidences:

        1.  -- Hemoconcentration assessed by an increase in hematocrit ≥20% from previous hematocrit

        2.  -- Signs of plasma leakage, such as pleural effusion or ascites, or an evidence of hypoalbuminemia

3.  DSS -- all items for DHF above, accompanied with evidence of circulatory failure, such as:[@b23-rmhp-7-045]

    -   Rapid and weak pulse; and

    -   Pulse pressure ≤20 mmHg.

        Or manifested by:

    -   Hypotension; and

    -   Cold body temperature or irritability.

Development data
----------------

The original data used to develop the score were obtained from three university-affiliated tertiary-care hospitals in Nakorn Sawan, Kampaeng Phet, and Uttaradit between 2007 and 2010 (n=777).

Validation data
---------------

The validation data were from similar patients as in the development data in another three university-affiliated tertiary-care hospitals in Phrae, Lamphun, and Chiang Mai during the same period (n=400).

Data analysis
-------------

The development data and the validation data were compared by exact probability tests or Student's *t*-tests or Wilcoxon's rank sum tests. The severity score was assigned to the patients based on the scoring system proposed from the earlier study, analyzed by multivariable ordinal logistic regression. Assigned item scores were derived by transformation of the coefficients of parameters ([Table 1](#t1-rmhp-7-045){ref-type="table"}).[@b21-rmhp-7-045] The proportions if correct prediction, underestimation, and overestimation in the development and the validation data were compared by areas under the receiver operating characteristic curves (AuROC). The predictive ability of the scoring system of both datasets was graphically compared by the probability or risk curves.

Results
=======

Patients in the development and the validation data were similar in the presence of the following symptoms and signs: vomiting, cough, bleeding, systolic blood pressure, diastolic blood pressure, hematocrit, aspartate aminotransferase, prothrombin time, partial thromboplastin time, but were different in gender, age, hepatomegaly, headache, myalgia, abdominal pain, rash, pleural effusion, petechiae, pulse pressure, hemoglobin, white cell count, lymphocytes, neutrophils, platelets, and alanine aminotransferase ([Table 2](#t2-rmhp-7-045){ref-type="table"}).

The severity score of patients in the development data was higher than in those in the validation data (5.6±4.1 versus 4.2±2.5, *P*\<0.001), and the percentage of DSS was higher (6.4% versus 1.5%, *P*\<0.001) ([Table 3](#t3-rmhp-7-045){ref-type="table"}).

In the validation data, classification of patients into three severity levels (DF, DHF, and DSS) yielded the following results.

-   Patients scoring less than 2.5 predicted DF correctly in 21.5% (n=86 from 208), with 1-level underestimation in 11% (n=44) and 2-level underestimation in 0.8% (n=3), a total of 11.8% (n=47).

-   Scores 2.5--11.5 predicted DHF correctly in 28.0% (n=112 from 157), with an underestimation in 6.8% (n=27) and an overestimation in 30.5% (n=122).

-   Scores above 11.5 predicted DSS correctly in 1.3% (n=5 from 35), with only 1-level overestimation in 0.3% (n=1) ([Table 4](#t4-rmhp-7-045){ref-type="table"}).

A total correct prediction was obtained in 50.8% (versus 60.7% in the development data), with an overall underestimation of 18.6% (versus 25.7%) and an overall overestimation in 30.8% (versus 13.5%).

The ability of the score to discriminate DF from DHF and DSS was different between the development and the validation data (AuROC =74.17% versus 70.76%, *P*=0.003). The ability to discriminate DSS from DF and DHF was also different (AuROC =88.77% versus 75.91%, *P*\<0.001), as shown in [Table 5](#t5-rmhp-7-045){ref-type="table"} and [Figure 1](#f1-rmhp-7-045){ref-type="fig"}.

Discussion
==========

The scoring systems for dengue infection in the past were reported to be successful when validated.[@b24-rmhp-7-045] A simple decision tree using existing data was also successful as a guideline to admit DHF patients into hospitals, reducing unnecessary admission of mild D F.[@b25-rmhp-7-045] A probability equation and a decision tree for DHF derived in 2004 and internally validated in 2007 was also successful in predicting DHF at first presentation, avoiding unnecessary hospital admission.[@b26-rmhp-7-045]

The scoring system proposed in the prior study[@b21-rmhp-7-045] was less accurate when validated to the new patients. This reduced accuracy may have occurred due to the fact that patients in the validation data were more severe or less severe than the development data, such as seen in this study.

However, from a clinical perspective, this scoring system would be useful in routine practice, as it requires only simple clinical data which can be obtained routinely and is usually available in all levels of patient care centers.

When applied to clinical practice, patients with a low score who are likely to have DF could be treated as outpatients, while those with a higher score who are likely to have DHF could be admitted, and those with the highest score who are likely to have DSS should be admitted for close monitoring, such as in an intensive care unit.

An impact of application of the score into routine clinical practice should be studied further to confirm its usefulness.

Conclusion
==========

Despite some difference between patients in the validation and in the development data, the scoring system could still discriminate dengue infection severity with clinically acceptable over- or underestimation. The proposed scoring system is likely to be generalized and applied to routine practice in similar patients and settings.
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###### 

Score assignment scheme for classifying dengue severity

  Clinical characteristic         Criteria   Assigned score
  ------------------------------- ---------- ----------------
  Age, years                      \>6        1
  ≤6                              0          
  Hepatomegaly                    Yes        8.5
  No                              0          
  Systolic blood pressure, mmHg   \<90       2
  ≥90                             0          
  White cell count, /μL           \>5,000    1
  ≤5,000                          0          
  Platelets, /μL                  ≤50,000    4.5
  \>50,000                        0          

**Notes:** Modified from Pongpan S, Wisitwong A, Tawichasri C, Patumanond J. Prognostic indicators for dengue infection severity. *Int J Clin Pediatr*. 2013;2(1):12--18.[@b8-rmhp-7-045] Copyright © 2013 Surangrat Pongpan et al.

###### 

Clinical characteristics of dengue patients in the development and the validation data

  ---------------------------------------------------------------------------------------------------------------------------
  Characteristics               Development\       Validation\         *P*-value[\*](#tfn2-rmhp-7-045){ref-type="table-fn"}
                                (n=777)            (n=400)             
  ----------------------------- ------------------ ------------------- ------------------------------------------------------
  Demographic                                                          

   Male, n (%)                  376 (48.4)         223 (55.8)          0.019

   Age, years                   9.6±3.3            10.3±3.4            0.002

  Mode of presentation, n (%)                                          

   Hepatomegaly                 89 (11.5)          11 (2.8)            \<0.001

   Headache                     408 (52.5)         301 (75.3)          \<0.001

   Myalgia                      126 (16.2)         164 (41.0)          \<0.001

   Vomiting                     516 (66.4)         255 (63.8)          0.366

   Cough                        246 (31.7)         142 (35.5)          0.191

   Abdominal pain               401 (51.6)         158 (39.5)          \<0.001

   Rash                         324 (41.7)         254 (63.5)          \<0.001

   Pleural effusion             54 (7.0)           16 (4.0)            0.030

   Petechiae                    67 (8.6)           76 (19.0)           \<0.001

   Any bleeding episodes        204 (26.3)         121 (30.3)          0.149

  Hemodynamic                                                          

   SBP, mmHg                    95.9±10.0          96.2±10.0           0.208

   DBP, mmHg                    58.3±8.2           58.5±7.5            0.270

   Pulse pressure, mmHg         31.0±8.0           32.6±20.1           \<0.001

  Hematological                                                        

   Hematocrit, (%)              40.3±5.0           40.3±5.2            0.781

   Hemoglobin, g/dL             13.1±1.6           13.0±1.7            0.044

   White cell count, /μL        4,171.5±1,800.3    3,612.4±1,202.1     \<0.001

   Lymphocytes, (%)             42.7±16.7          40.8±15.4           0.003

   Neutrophils, (%)             47.1±18.5          43.6± 19.0          \<0.001

   Platelets, /μL               97,569.5±8,707.0   111,963.2±6,692.2   \<0.001

  Biochemical                                                          

   AST, IU/L                    351.7±522.7        477.5±437.0         0.152

   ALT, IU/L                    135.8±324.9        181.0±269.1         0.048

   PT, seconds                  13.7±6.8           13.3±2.8            0.796

   PTT, seconds                 42.0±11.5          36.4±9.1            0.094

  Case management, n (%)                                               

   Inbound referral             169 (21.8)         54 (13.5)           0.001

   Discharged                                                          

    Alive                       775 (99.7)         400 (100.0)         0.551

    Outbound referral           2 (0.3)            0 (0)               

    Died in hospital            0 (0)              0 (0)               
  ---------------------------------------------------------------------------------------------------------------------------

**Note:**

*P*-value from exact probability test or *t*-test or Wilcoxon's rank sum test.

**Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase; DBP, diastolic blood pressure; PT, prothrombin time; PTT, partial thromboplastin time; SBP, systolic blood pressure; SD, standard deviation.

###### 

Score-derived dengue severity levels in the development and the validation data

  --------------------------------------------------------------------------------------------------------------------
  Score-classified severity levels   Development\   Validation\   *P*-value
                                     (n=777)        (n=400)       
  ---------------------------------- -------------- ------------- ----------------------------------------------------
  Mean score (± SD)                  5.6±4.1        4.2±2.5       \<0.001

  Range                              0--18          0--18         

  Severity levels, n (%)                                          

   DF                                451 (58.0)     133 (33.3)    \<0.001[\*](#tfn4-rmhp-7-045){ref-type="table-fn"}

   DHF                               276 (35.5)     261 (65.3)    

   DSS                               50 (6.4)       6 (1.5)       
  --------------------------------------------------------------------------------------------------------------------

**Note:**

*P*-value from non-parametric test for trend.

**Abbreviations:** DF, dengue fever; DHF, dengue hemorrhagic fever; DSS, dengue shock syndrome; SD, standard deviation.

###### 

Score-classified severity and criterion-classified dengue severity in the validation data

  Score-classified severity levels   Score range   Criterion-classified severity levels   Risk estimation validity[\*](#tfn6-rmhp-7-045){ref-type="table-fn"}                            
  ---------------------------------- ------------- -------------------------------------- --------------------------------------------------------------------- ---------- ------ ------ ------
  Mean ± SD                                        3.3±1.8                                4.4±2.1                                                               6.5±3.5                  
  IQR                                              2.0--4.8                               3.8--4.8                                                              4.8--6.8                 
  DF                                                                                                                                                                                     
   n=133                             \<2.5         86                                     44                                                                    3          --     21.5   11.8
  DHF                                                                                                                                                                                    
   n=261                             2.5--11.5     122                                    112                                                                   27         30.5   28.0   6.8
  DSS                                                                                                                                                                                    
   n=6                               \>11.5        0                                      1                                                                     5          0.3    1.3    --
                                                                                                                                                                Total      30.8   50.8   18.6

**Note:**

Percentage of total patients.

**Abbreviations:** DF, dengue fever; DHF, dengue hemorrhagic fever; DSS, dengue shock syndrome; IQR, interquartile range; SD, standard deviation.

###### 

Discriminative performance of the dengue severity score in the development data and the validation data

  Prediction/discrimination   Development (n=777)   Validation (n=400)   *P*-value                  
  --------------------------- --------------------- -------------------- ----------- -------------- ---------
  DHF and DSS versus DF       74.17                 72.94--75.37         70.76       68.83--72.43   0.003
  DSS versus DF and DHF       88.77                 87.88--89.64         75.91       74.18--77.57   \<0.001

**Abbreviations:** AuROC, area under receiver operating characteristic curve; CI, confidence interval; DF, dengue fever; DHF, dengue hemorrhagic fever; DSS, dengue shock syndrome.
